| ǥ :
|
ȣ - 480373 25 |
| Drug Eluting Stent Implantation in Primary Coronary Intervention is Safe or Not |
| Division of Cardiology, Internal Medicine, Dongsan Medical Center, Keimyung University |
| Chang-Wook Nam, Seung-Ho Hur, Kwon-Bae Kim, Young-Soo Lee, Chang-Wook Park, Yun-Kyeong Cho, Su-Nam Yang, Sang-Hoon Lee, Seong-Wook Han, Kee-Sik Kim, Yoon-Nyun Kim |
BACKGROUND: Drug-eluting stent (DES) implantation for acute myocardial infarction markly reduced the risk of major adverse events and repeat intervention. But the safety of DES implantation for primary percutaneous coronary intervention (PCI) is not well known. OBJECTIVES: This study investigated the clinical outcomes between primary PCI and delayed PCI in the patients with acute myocardial infarction treated with DES. METHODS: Since April 2003 to June 2004, 138 patients (217 lesions) with acute myocardial infarction underwent PCI with DES implantation. Patients were divided to primary and delayed PCI groups. The clinical characteristics, PCI result and clinical outcomes were evaluated. RESULTS: Clinical follow-up was available in 97.9%. Mean follow-up duration was 6.9 months. See as a following table. CONCLUSIONS: DES implantation in primary PCI for the patients with more complex condition was safe and effective as use in delayed PCI.
|
|
|
Group
(n =
patient/lesion) |
Primary PCI
(n = 24/31) |
Delayed PCI
(n = 118/186) |
p Value |
|
Male (%)
Age, yrs
DM (%)
Ejection fraction
1/2/3
VD (%)
Pre-PCI RD/MLD,
mm
Lesion length, mm
Stent length, mm
Stent size, mm
Post-PCI MLD, mm
Angina/Death (%)
Nonfatal MI/TVR
(%)
MACE (%) |
79.2
59.5 ± 11.8
32.3
43.3
50.0/25.0/25.0
3.14±0.43/0.18±0.24
26.10 ± 11.69
27.06 ± 5.57
3.12 ± 0.36
3.00 ± 0.45
8.3/4.2
4.2/0
8.3 |
67.8
61.1 ± 11.3
22.0
47.3
33.1/43.2/23.7
3.09±0.33/0.45±0.27
22.70 ± 9.91
24.37 ± 5.39
3.11 ± 0.29
3.02 ± 0.35
10.4/0
0/2.2
2.6 |
0.196
0.533
0.155
0.003+
0.196
0.495/0.000+
0.097
0.016+
0.875
0.763
0.551/0.173
0.173/0.530
0.206 |
DM;
diabetes, VD; vessel disease, RD; reference diameter, MLD; minimal diameter,
TVR; target vessel revascularization, MACE; major adverse cardiac event, +; p value <
0.05
|
|
|
